RNRichard Julius Nies

Richard Julius Nies

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard Julius Nies has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Contemporary real-world treatment of cardiac transthyretin amyloidosis with tafamidis: a long-term multicentre study

    by Richard J Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, et al.

    Aims: Tafamidis was the first drug approved for transthyretin amyloid cardiomyopathy (ATTR-CM), but contemporary real-world evidence is lacking. Methods and results: This retrospective, multicentre study included ATTR-CM patients enrolled after commercial availability of tafamidis 61 mg in Germany (April 2020 to March 2021), with treatment initiation based on physician clinical judgement. Primary and secondary endpoints were all-cause mortality and the composite of all-cause mortality and/or heart failure (HF) hospitalization, respectively. The cohort comprised 329 patients (median age 80 [76–83] years, 85% male and 8% variant ATTR) and 80% received tafamidis. During a median follow-up of 39 [18–48] months, 21% of patients died and 42% reached the composite endpoint. Tafamidis-treated patients had a 3-year survival of 86% and an event-free survival of 63%. After propensity-score matching for age, New York Heart Association (NYHA) class, National Amyloidosis Centre (NAC) stage, and serum albumin, tafamidis was significantly associated with lower all-cause mortality (hazard ratio [HR] 0.28; 95%-confidence interval [CI] 0.13–0.61; P = .001) and fewer composite events (HR 0.56; 95%-CI 0.33–0.97; P = .039). In tafamidis-treated patients, primary and secondary endpoints were associated with advanced NAC stage (P < .031; P < .009), age ≥80 years (P = .022; P = .004), and serum albumin ≤42.5 g/L (P = .015; P < .001), whereas NYHA class ≥III predicted only the composite endpoint (P = .059; P < .001). Conclusions: This study provides long-term real-world outcome data for ATTR-CM patients treated with tafamidis based on physician clinical judgement. Adverse outcomes were strongly predicted by low serum albumin, advanced NAC stage, and older age, emphasizing the importance of early diagnosis and timely therapy of ATTR-CM.


  • Midterm Clinical and Echocardiographic Outcomes After Transcatheter Aortic Valve Replacement in Patients With Severe Bicuspid Aortic Valve Stenosis

    by Stephan Nienaber, Katharina Krabichler, David Fahlbusch, Victor Mauri, Jan Althoff, Samuel Lee, Jonathan Curio, Henning Guthoff, Karl Finke, Alexander Hof, et al.

    Background: Outcomes >2 years after transcatheter aortic valve replacement (TAVR) for bicuspid aortic valves (BAV) are scarce, and differences between balloon‐expandable transcatheter heart valves (THVs) and self‐expandable (SE‐THVs) are not yet well established. Methods: This study aims to report midterm outcomes after TAVR in patients with BAV and includes 92 patients undergoing TAVR for BAV stenosis at the University Hospital Cologne between 2018 and 2023. The primary outcomes were all‐cause death, cardiovascular death, and stroke over a mean follow‐up of 2.9 years. Results: Among 92 consecutive patients undergoing TAVR for BAV stenosis (median age: 78.8 years), the incidence of all‐cause death, cardiovascular death, and stroke was 26.1%, 18.5%, and 14.1%, respectively, at 2.9 years, with no differences between balloon‐expandable THVs and SE‐THVs. Pacemaker implantation tended to be more frequent in the SE‐THV group. Periprocedural complications were rare, as reflected by a high Valve Academic Research Consortium‐3 technical success rate of 96.7%. Postprocedural transvalvular gradients were favorable, with SE‐THV showing lower values than balloon‐expandable THV (8.0 versus 10.5 mm Hg, P =0.007). Moderate or severe paravalvular regurgitation was uncommon, with no differences between groups, although a trend toward more relevant paravalvular regurgitation with SE‐THV was observed. Conclusions: TAVR for BAV is feasible with both SE‐THV and balloon‐expandable ‐THV, achieving high technical success and low complication rates. Hemodynamic differences were observed, but mortality and stroke did not differ significantly between groups. Overall outcomes remain suboptimal, highlighting the need for randomized trials comparing valve types and TAVR with surgery for patients with BAV.

  • Open Access

    Modified essential frailty toolset for risk stratification in transcatheter mitral and tricuspid valve repair

    by Matthieu Schäfer, Clemens Metze, Caroline F. Hasse, Jan Althoff, Thorsten Gietzen, Karl Finke, Jennifer von Stein, Philipp von Stein, Jan Wrobel, Richard J. Nies, et al.

    Background: Current guidelines recommend frailty assessment for risk stratification of candidates for transcatheter mitral and tricuspid valve repair (TMTVR), but it remains unclear which frailty score is most appropriate. Methods: In a retrospective monocentric analysis of patients who received TMTVR, a modified version of the essential frailty toolset (EFT) was calculated from four categories: gait speed, cognitive impairment, hemoglobin, and serum albumin. Cox proportional hazards models were used to examine the association between EFT frailty and all-cause mortality. Results: A total of 206 patients were analyzed; median age was 76 [72–82] years, and 55% were male. According to the EFT, 49 patients (24%) were non-frail, 127 patients (62%) were pre-frail, and 30 patients (15%) were frail. Estimated survival at 2 years was 88 ± 5% for non-frail patients, 74 ± 5% for pre-frail patients, and 62 ± 10% for frail patients, with a hazard ratio of 1.54 (95% CI 1.16–2.04; p = 0.003) per standard deviation of EFT score. This association remained virtually unchanged when adjusted for other risk factors and Fried physical frailty, but disappeared when adjusted for the multidimensional prognostic index (MPI), which is based on a comprehensive geriatric assessment. A stepwise approach using EFT in all patients and MPI only in pre-frail EFT patients resulted in two risk categories with a 4.4-fold (95% CI 2.3–9.4) difference in 2-year mortality between categories. Conclusions: The EFT has prognostic value for patients undergoing TMTVR. Due to its simplicity, the EFT could serve as a first-line frailty assessment tool to guide therapeutic decision-making, potentially in a stepwise approach with MPI. Graphical Modified Essential Frailty Toolset (EFT) (adapted from J. Afilalo et al., JACC [2017]) [14] and Kaplan–Meier survival plots for all-cause mortality by frailty according to the EFT score


  • Open Access

    Cardiac transthyretin amyloidosis in aortic valve replacement: RAISE score performance in the postoperative setting

    by Richard J. Nies, Svenja Ney, Jasper F. Nies, Katharina Seuthe, Jan Grobecker, Friedrich Gruenagel, Stephan Nienaber, Merve Kural, Sascha Macherey-Meyer, Matthieu Schäfer, et al.

    Aims: The RAISE Score, encompassing five domains ( R emodeling, A ge, I njury, S ystemic, E lectrical), was proposed to screen for transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with aortic stenosis (AS), but is not routinely used. This study evaluated its performance following aortic valve replacement (AVR). Methods: This single-center, prospective, observational study included patients aged ≥ 60 years with end-diastolic interventricular septum thickness (IVSd) ≥ 12 mm, who underwent hydroxydiphosphonate (HDP) bone scintigraphy after AVR between March 2021 and July 2024. The diagnostic performance of the RAISE Score assessed at 30-day follow-up and of simpler screening parameters for pathological HDP uptake (Perugini 1–3) were analyzed, along with their association with all-cause mortality and heart failure (HF) hospitalization. Results: Among 131 included patients (median age 81 years; 64% male) pathological HDP uptake was found in 21 (16%), and 11 (8.4%) were diagnosed with ATTR-CM. A RAISE Score ≥ 2 demonstrated 76% sensitivity and 56% specificity for pathological bone scintigraphy, while a Score ≥ 3 showed 62% sensitivity and 78% specificity. The parameters age ≥ 83 years and the combination of carpal tunnel syndrome (CTS) and/or N-terminal pro-B-type natriuretic peptide (NT-proBNP) ≥ 1,400 pg/mL performed similarly to the RAISE Score. Cardiac HDP uptake showed a strong trend toward HF hospitalization (HR [95%-CI]: 5.81 [0.93–36.20]; p = 0.060) and all-cause mortality (HR [95%-CI]: 3.27 [0.95–11.24]; p = 0.060). CTS and/or NT-proBNP ≥ 1,400 pg/mL was significantly associated with higher all-cause mortality (HR [95%-CI]: 3.92 [1.04–14.84]; p = 0.044), whereas the RAISE Score was not. Conclusion: After AVR, the complex RAISE Score showed lower sensitivity than originally reported, while simpler parameters demonstrated comparable predictive value for ATTR-CM screening. Advanced age, CTS history and elevated NT-proBNP levels seem most valuable for identifying candidates for bone scintigraphy. Graphical A total of 131 patients aged ≥ 60 years, with an IVSd ≥ 12 mm and an AVR between March 2021 and July 2024, underwent standard diagnostic evaluation for ATTR-CM, including HDP bone scintigraphy. Pathological findings on bone scintigraphy (Perugini Score 1–3) were observed in 16% of the patients and were associated with worse clinical outcomes. The performance of the proposed RAISE Score [11], along with simplified or modified screening parameters, was evaluated in predicting both pathological scintigraphy results and clinical outcomes. ATTR-CM = transthyretin amyloidosis cardiomyopathy; AVR = aortic valve replacement; CTS = carpal tunnel syndrome; HDP = hydroxydiphosphonate; IVSd = interventricular septum thickness at end-diastole; NT-proBNP = N-terminal pro-B-type natriuretic peptide.


  • Open Access

    Safety and effectiveness of oscillatory whole-body vibration training on exercise capacity and physical performance in aortic valve stenosis patients prior to transcatheter aortic valve implantation: a randomized clinical trial

    by Johannes Klaus, Felix Gerhardt, Stephan Nienaber, Victor Mauri, Kathrin Möllenhoff, Richard Nies, Elmar Kuhn, Stephen Gerfer, Ilija Djordjevic, Samuel Lee, et al.

    Background: Exercise training is generally discouraged in patients with severe symptomatic aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) due to safety concerns. However, whole-body vibration (WBV) exercise could offer a novel approach to improve exercise capacity and quality of life, though its effects remain unclear in this population. Methods: Thirty patients with AS scheduled for TAVI were prospectively and randomly assigned to either the WBV group (12 sessions, 30 min each over 4 weeks) or a control group. Assessments of cardiopulmonary exercise testing (CPET), 6-min walking distance (6MWD) and health-related quality of life (HRQoL) questionnaires were conducted at baseline (V1), one day before TAVI (V2) and at short-term follow-up (V3). WBV was conducted between V1 and V2. Results: For the analysis at V1 and V2 16 patients in the WBV group and 14 in the control group were included. Mean age was 79.7 ± 5.22 years, with a mean aortic valve area of 0.75 ± 0.21 cm2. Peak V’O2 increased by 0.3 mL*min-1*kg-1 in the WBV group versus a decrease of − 1.4 mL*min-1*kg-1 in the control group (difference, 1.7 mL*min-1*kg-1; 95% CI, [0.2 to 3.2], p = 0.03). Peak power improved by 5.1 W in the WBV group compared to a decline of − 4.5 W in the control group (difference, 9.6 W; 95% CI, [2.1 to 17.1], p = 0.01). The WBV group also showed a non-significant improvement in 6MWD (34 m vs. − 8 m in the control group; difference, 42 m; 95% CI, [-10 to 93], p = 0.11). No serious adverse events occurred in the WBV group. Conclusion: This pilot study demonstrated that a WBV exercise program is feasible, safe, and showed potential to preserve exercise capacity as well as physical performance in AS patients scheduled for TAVI. Graphical


  • Open Access

    Comparison of Valve Academic Research Consortium (VARC)‐2 and VARC‐3 Criteria for Bleeding Complications After Transcatheter Aortic Valve Replacement

    by Stephan Nienaber, Janosch Himken, Max Meertens, Victor Mauri, Samuel Lee, Jonathan Curio, Elmar Kuhn, Richard Nies, Kaveh Eghbalzadeh, Johannes Dohr, et al.

    Background: The Valve Academic Research Consortium (VARC) has updated criteria for periprocedural bleeding after transcatheter aortic valve replacement. However, clinical validation of the VARC‐3 bleeding definition is scarce. The aim of this study was to evaluate incidence, associated variables, and clinical impact of VARC‐3 bleeding. Methods: The study included 2227 patients with severe aortic stenosis undergoing transcatheter aortic valve replacement between 2018 and 2023 at the University Hospital Cologne. VARC‐3 bleeding during the index hospitalization were analyzed. Incidence, variables associated with bleeding, and impact on 30‐day mortality were evaluated by comparison to the VARC‐2 criteria. All data were prospectively collected. Results: VARC‐3 bleeding was 2.5 times more prevalent than VARC‐2 (13.9% versus 34.4%), as VARC‐3 includes nonattributable blood loss >3 g/dL as a bleeding event. Chronic kidney disease, thoracotomy access, dual antiplatelet therapy ( P P =0.023) were variables associated with VARC‐3 bleedings. Type 3 bleeding (VARC‐3) was associated with an increased 30‐day mortality (hazard ratio [HR], 2.89 [95% CI, 1.35–6.19], P =0.006). VARC‐2 major and life‐threatening bleeding events were associated with increased 30‐day mortality as well (HR, 2.74 [95% CI, 1.26–5.95], P =0.011 and HR, 29.60 [95% CI, 17.42–50.30], P <0.001). Conclusions: The VARC‐3 criteria present a refined classification for bleeding with prognostic relevance. However, the VARC‐2 criteria demonstrate precision and clear correlation with increasing mortality risk proportional to the severity of bleeding too, showing even greater predictive accuracy in the transfemoral cohort. These findings require further validation with similar or even larger patient cohorts.


  • Open Access

    Invasive Strategy With Intended Percutaneous Coronary Intervention Versus Conservative Treatment in Older People With ST‐Segment–Elevation Myocardial Infarction: A Meta‐Analysis

    by Sascha Macherey‐Meyer, David Dilley, Sebastian Heyne, Max Maria Meertens, Richard Julius Nies, Samuel Lee, Christoph Adler, Stephan Baldus, Ingo Eitel, Thomas Stiermaier, et al.

    Background: Patients ≥80 years old were underrepresented or excluded from landmark trials demonstrating the superiority of primary percutaneous coronary intervention (PCI) in ST‐segment–elevation myocardial infarction. The current meta‐analysis assessed the effects of an invasive strategy with intended PCI compared with conservative treatment in older people (≥80 years) with ST‐segment–elevation myocardial infarction. Methods: A structured literature search was performed. The primary outcome was overall survival. Secondary outcome analyses included but were not limited to 30‐day and 1‐year mortality. Results: Thirteen studies reporting on 102 158 older adults were included. Of these, 31 629 (31%) were assigned to PCI and 70 529 (69%) were treated conservatively. The overall survival was 76.5% in PCI and 67.2% in conservative treatment at the time of longest available follow‐up (odds ratio [OR], 2.18 [95% CI, 1.79–2.66], P I 2 =88%, favoring PCI). The follow‐up period ranged from 30 days to 26.5 months. The 30‐day. (OR, 0.39 [95% CI, 0.31–0.50], P I 2 =0%) and 1‐year mortality (OR, 0·34 [95% CI, 0.25–0.46], P I 2 =0%), were lower in the PCI group. Conclusions: This meta‐analysis indicates a potential underuse of PCI in older adults with ST‐segment–elevation myocardial infarction. PCI was advantageous in short‐ and long‐term survival, but these results were affected by confounding. Nonetheless, every second patient not referred for invasive treatment survived at least 1 year. These findings have hypothesis generating implications, but they indicate ageism and emphasize that PCI should not be automatically withheld in older patients.


  • Open Access

    Outpatient diuretic intensification: a simple prognostic marker in cardiac transthyretin amyloidosis

    by Richard J. Nies, Svenja Ney, Jasper F. Nies, Katharina Seuthe, Lukas Klösges, Monique Brüwer, Stephan Nienaber, Sascha Macherey-Meyer, Matthieu Schäfer, Roman Pfister

    Background: Currently, simple clinical parameters indicating disease progression are lacking in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate the prognostic value of outpatient diuretic intensification (ODI) in ATTR-CM patients. Methods: This retrospective study examined ATTR-CM patients at a tertiary care center between August 1, 2020, and June 30, 2023. ODI was defined as any loop diuretic increase within 6 months after baseline visit, and its impact on all-cause mortality and hospitalization for heart failure (HF) was analyzed. Results: Altogether, 182 patients were included (median age 80 [76; 84] years; 88% male), and 25% experienced ODI (median increase 10 [10; 40] mg furosemide equivalent). Independent predictors of ODI were higher baseline New York Heart Association (NYHA) class and polyneuropathy. Both any ODI and the magnitude of furosemide equivalent increase were significantly associated with mortality and HF hospitalization during a median follow-up of 17 months. After adjusting for baseline NYHA class and National Amyloidosis Centre stage, significantly increased risk of all-cause mortality (hazard ratio [HR] 2.38, 95% confidence interval [CI] 1.03–5.53; p = 0.043) and HF hospitalization (HR 3.27, 95% CI 1.41–7.60; p  = 0.006) persisted in patients with ODI. Its prognostic value was similar in strata of age, ATTR subtype, previous cardiac decompensation, biomarkers, left ventricular ejection fraction, six-minute walk distance, and tafamidis treatment. Conclusion: ODI occurred in one in four ATTR-CM patients within 6 months and was associated with more severe baseline amyloid organ manifestations. ODI and the magnitude of diuretic dose increase provide easily assessable clinical markers of disease progression in patient monitoring. Graphical A total of 182 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR-CM) were analyzed for an increase in loop diuretic dosage within the first 6 months after the baseline visit. Twenty-five percent of the cohort experienced outpatient diuretic intensification (ODI), with independent predictors being dyspnea in higher New York Heart Association (NYHA) class and polyneuropathy (PNP). ODI was significantly associated with all-cause mortality, and its prognostic value remained consistent across various risk factors


  • Open Access

    Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge‐to‐Edge Repair in Patients With Atrial Fibrillation: A Single‐Center Observational Study

    by Jan‐Hendrik Schipper, Anne‐Sophie Sommer, Richard Julius Nies, Clemens Metze, Max Maria Meertens, Jonas Wörmann, Sebastian Dittrich, Jan‐Hendrik van Den Bruck, Arian Sultan, Jakob Lüker, et al.

    Background: Mitral valve transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a viable therapy option in patients with severe mitral regurgitation and high surgical risk. Although atrial fibrillation is common among patients undergoing M‐TEER, the optimal anticoagulatory treatment after the intervention is unknown. Methods: A single‐center retrospective observational analysis was conducted using data from the M‐TEER registry at the University Hospital Cologne collected from 2019 untill 2021 including patients undergoing M‐TEER between November 2012 and April 2019. Patients with atrial fibrillation receiving consistent anticoagulation following M‐TEER were categorized into a direct oral anticoagulant or a vitamin K antagonist (VKA) group. The primary end point was a composite of ischemic cerebrovascular and bleeding events. Additionally, overall survival was assessed. Results: Among 613 patients undergoing M‐TEER, 206 met the inclusion criteria, with 61 receiving direct oral anticoagulants and 145 receiving VKAs. After a median follow‐up of 833 (interquartile range, 355–1271) days, the incidence of the composite primary end point did not differ between direct oral anticoagulant and VKA groups (hazard ratio [HR], 0.51 [95% CI, 0.23–1.12]; P =0.07). Similarly, rates of ischemic cerebrovascular events and bleeding events were similar between groups. However, the overall mortality rate was higher in the VKA group (HR, 2.56 [95% CI, 1.54–4.26]; P =0.002). In the multivariable analysis, oral anticoagulation with a VKA was an independent predictor for death (adjusted HR, 2.23 [95% CI, 1.08–5.06]; P =0.03). Conclusions: Our findings suggest that direct oral anticoagulants may offer comparable efficacy and safety to VKAs in preventing thromboembolic events following M‐TEER in patients with atrial fibrillation. Further randomized trials are needed to confirm these results and establish optimal anticoagulation strategies in this patient population.


  • Open Access

    Hematopoietic PI3Kδ deficiency aggravates murine atherosclerosis through impairment of Tregs

    by Mario Zierden, Eva Maria Berghausen, Leoni Gnatzy-Feik, Christopher Millarg, Felix Simon Ruben Picard, Martha Kiljan, Simon Geißen, Apostolos Polykratis, Lea Zimmermann, Richard Julius Nies, et al.

    Chronic activation of the adaptive immune system is a hallmark of atherosclerosis. As PI3Kδ is a key regulator of T and B cell differentiation and function, we hypothesized that alleviation of adaptive immunity by PI3Kδ inactivation may represent an attractive strategy counteracting atherogenesis. As expected, lack of hematopoietic PI3Kδ in atherosclerosis-prone Ldlr –/– mice resulted in lowered T and B cell numbers, CD4 + effector T cells, Th1 response, and immunoglobulin levels. However, despite markedly impaired peripheral pro-inflammatory Th1 cells and atheromatous CD4 + T cells, the unexpected net effect of hematopoietic PI3Kδ deficiency was aggravated vascular inflammation and atherosclerosis. Further analyses revealed that PI3Kδ deficiency impaired numbers, immunosuppressive functions, and stability of regulatory CD4 + T cells (Tregs), whereas macrophage biology remained largely unaffected. Adoptive transfer of wild-type Tregs fully restrained the atherosclerotic plaque burden in Ldlr –/– mice lacking hematopoietic PI3Kδ, whereas PI3Kδ-deficient Tregs failed to mitigate disease. Numbers of atheroprotective B-1 and pro-atherogenic B-2 cells as well as serum immunoglobulin levels remained unaffected by adoptively transferred wild-type Tregs. In conclusion, we demonstrate that hematopoietic PI3Kδ ablation promotes atherosclerosis. Mechanistically, we identified PI3Kδ signaling as a powerful driver of atheroprotective Treg responses, which outweigh PI3Kδ-driven pro-atherogenic effects of adaptive immune cells like Th1 cells.